GSK
GSK plcPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 4 Roofers Local No. 149 Pension Fund, on behalf of itself and…
- Mar 31 Louisiana Wholesale Drug Co., Inc., et al. v…
- Jun 16 GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC v…
- Sep 9 Trial readout: Results Pending: dTpa vaccine (Phase 3), Completed 5d ago
- Sep 18 Trial readout: Results Pending: Flu mRNA (Formulation B1) (Phase 2), Comp…
- Oct 12 Trial readout: Results Pending: dTpa vaccine (Phase 3), Completed 38d ago
- Oct 12 Trial readout: Results Pending: iNTS-GMMA Dose C (Phase 2), Completed 67d…
- Oct 18 Trial readout: Results Pending: Flu mRNA (Formulation B1) (Phase 2), Comp…
- Oct 19 ▲ GSK announced FDA approval of Jemperli (dostarlimab) as the first an…
- Oct 19 ▲ GSK announced first global phase Ib data for its B7-H3-targeted ADC,…
- Oct 21 ▲ GSK announced FDA approval of Hibsago (bepirovirsen) for chronic hep…
- Oct 29 ▼ Jefferies downgrades
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q3 2026: 25 added (2 new), 15 trimmed or exited. Largest new: Aberdeen Group $28.1M, Renaissance Technologies $22.5M.
- AnalystsBULLISH
15 of 34 rate it Buy or better. Median target $58.00 (+15%).
- Short sellersSTEADY
Short interest +10.8% to 16.15M shares. 3.2 days to cover, ≈0.8% of shares.
- TrendUPTREND
2% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 24.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $104.5M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $99.9M |
| BANK OF MONTREAL /CAN/ | TRIM | $97.5M |
| JPMORGAN CHASE & CO | TRIM | $58.6M |
| SEI INVESTMENTS CO | TRIM | $38.4M |
| Aberdeen Group plc | NEW | $28.1M |
| RENAISSANCE TECHNOLOGIES LLC | NEW | $22.5M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | $20.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
34 analystsPrice is inside the target range. Median implies +15%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 29, 2026 | Jefferies DOWNGRADE | Hold |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | None | None | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
64 filings · 19 bullish · 2 bearish · 2 mixed · 41 neutral- NEUTRAL 6-KNov 13, 2026
GSK announced that the EMA's CHMP has issued a positive opinion recommending a label update for…
Monitor European Commission decision expected within 2-3 months; if adopted, watch for national immunization program updates in countries with existing infant MenB programs, as adolescent booster…
- NEUTRAL 6-KNov 12, 2026
GSK filed a Form 6-K reporting routine share acquisitions by multiple PDMRs (directors and senior…
Routine share plan transactions have no material impact on GSK's stock. Monitor upcoming quarterly results for fundamental drivers.
- NEUTRAL 6-KNov 6, 2026
GSK published provisional dividend dates for 2027, a routine administrative filing with no…
Routine dividend schedule update with no financial data. Monitor Q4 2026 results release for actual dividend declaration and amount.
- NEUTRAL 6-KNov 2, 2026
GSK filed a routine total voting rights notification under UK disclosure rules, reporting…
No trading signal from this filing. The voting rights count is a standard periodic update with no change in share structure or corporate action.
All GSK filing & press-release reports (64)
- 6-K reportNov 13, 2026
- 6-K reportNov 12, 2026
- 6-K reportNov 6, 2026
- 6-K reportNov 2, 2026
- 6-K reportOct 28, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 26, 2026
- 6-K reportOct 21, 2026
- 6-K reportOct 19, 2026
- 6-K reportOct 19, 2026
- 6-K reportOct 15, 2026
- 6-K reportOct 14, 2026
- 6-K reportOct 13, 2026
- 6-K reportOct 13, 2026
- INST-CLUSTER reportOct 12, 2026
- 6-K reportOct 8, 2026
- 6-K reportOct 6, 2026
- 6-K reportOct 1, 2026
- 6-K reportSep 24, 2026
- 6-K reportSep 22, 2026
- 6-K reportSep 15, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 11, 2026
- 6-K reportSep 10, 2026
- 6-K reportSep 10, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportAug 26, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 18, 2026
- 6-K reportAug 11, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 28, 2026
- 6-K reportJul 28, 2026
- 6-K reportJul 28, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 17, 2026
- 6-K reportJul 17, 2026
- 6-K reportJul 16, 2026
- 6-K reportJul 15, 2026
- 6-K reportJul 14, 2026
- 6-K reportJul 13, 2026
- 6-K reportJul 13, 2026
- 6-K reportJul 10, 2026
- 6-K reportJul 9, 2026
- 6-K reportJul 9, 2026
- COURT-RULING reportMar 31, 2026
- 6-K reportJul 1, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 17, 2026
- COURT-RULING reportJun 16, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 12, 2026
- 6-K reportJun 11, 2026
- COURT-RULING reportMar 4, 2026
- 6-K reportApr 13, 2026
- 6-K reportMar 30, 2026
- 6-K reportMar 26, 2026